The role of colony stimulating factors and immunoglobulin in the prevention and treatment of neonatal infection

Carr, Robert

doi:10.1136/archdischild-2011-301269

Cited by 8 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the findings with antistaphylococcal immunoglobulins, studies of G-CSF and GM-CSF in neutropenic neonates have not been successful in preventing infections in preterm infants [15]. One theory is that targeting more than one factor of the immune system could improve the efficacy of these approaches to prevent infections in an immunocompromised host such as the premature neonate.…”

Section: Expert Opinionmentioning

confidence: 86%

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

Patel

Kaufman

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

These studies demonstrated safety and tolerability of pagibaximab with no observed reduction in sepsis. Reported adverse events in both treatment and placebo groups were similar and consistent with events commonly observed in VLBW infants. Antistaphylococcal immunoglobulins alone have been unsuccessful in preventing nosocomial infections. Further investigations need to evaluate any potential immunomodulating products in preterm animal models prior to human studies. Future studies are required to determine how to best augment the immature immune system, likely through the use of multiple immunomodulating agents to successfully prevent infections in preterm infants.

show abstract

Section: Expert Opinionmentioning

confidence: 86%

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

Patel

Kaufman

2015

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

“…The thrombocytopenia of placental insufficiency is due to reduced platelet production, but endogenous TPO levels are already high. Furthermore, the analogous precedent of using G-CSF or GM-CSF to increase neutrophil production and boost marrow reserves of mature neutrophils in infants with or at risk of neutropenia did not translate into clinical benefit [38]. …”

Section: Alternative Treatments For Neonatal Thrombocytopeniamentioning

confidence: 99%

Neonatal Thrombocytopenia and Platelet Transfusion - A UK Perspective

2014

Self Cite

View full text Add to dashboard Cite

Five percent of newborn infants admitted to UK neonatal units during a recent study developed a platelet count <60 × 10⁹/l, and 60% of these were transfused platelets. This review summarises the common causes and mechanisms of thrombocytopenia in the newborn. Relevant evidence relating the platelet count to the risk of haemorrhage is reviewed, and current UK guidance on transfusion thresholds outlined. The UK policy for the provision of platelets for transfusion to neonates is described, including the particular requirements for neonatal allo-immune thrombocytopenia. Finally, we look towards the future and prospects for reducing the need to expose newborns to donor-derived platelets.

show abstract

Drug monographs

2014

Neonatal Formulary 7

View full text Add to dashboard Cite

The role of colony stimulating factors and immunoglobulin in the prevention and treatment of neonatal infection

Cited by 8 publications

References 32 publications

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

Neonatal Thrombocytopenia and Platelet Transfusion - A UK Perspective

Drug monographs

Contact Info

Product

Resources

About